









Markets
/
Stocks
/
nasdaq-gnft
/

Genfit SA

GNFT

4.065USD

-0.045-1.09%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

203.26MMarket Cap

--P/E TTM



Genfit SA

4.065

-0.045-1.09%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Genfit SA

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Genfit SA's Score

Industry at a Glance

Industry Ranking

269 / 501

Overall Ranking

480 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

8.683

Target Price

+111.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Genfit SA Highlights

StrengthsRisks

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 147.99% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 62.29M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 145.37, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.73K shares, decreasing 89.49% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Genfit SA's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is 145.37, which is 49.43% below the recent high of 217.22 and 35.91% above the recent low of 93.17.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 269/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.71, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Genfit SA is 8.85, with a high of 9.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

8.683

Target Price

+111.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Genfit SA

GNFT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.99, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.59 and the support level at 3.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.20

Change

-0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.033

Sell

RSI(14)

49.802

Neutral

STOCH(KDJ)(9,3,3)

65.022

Buy

ATR(14)

0.199

High Vlolatility

CCI(14)

15.453

Neutral

Williams %R

44.371

Buy

TRIX(12,20)

-0.102

Sell

StochRSI(14)

81.934

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.983

Buy

MA10

4.013

Buy

MA20

4.121

Sell

MA50

4.066

Sell

MA100

3.995

Buy

MA200

3.922

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Morgan Stanley & Co. International Plc

27.42K

+7.45%

AllianceBernstein L.P.

22.36K

+148.94%

Citadel Advisors LLC

18.76K

+52.16%

UBS Financial Services, Inc.

4.08K

+30.89%

Geode Capital Management, L.L.C.

3.21K

Osaic Holdings, Inc.

225.00

Principal Securities Inc

24.00

Qube Research & Technologies Ltd

-100.00%

BofA Global Research (US)

1.00

-94.12%

Millennium Management LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.